First results of two multi-center international Phase 1 dose-escalation and -expansion clinical trials of novel T-cell bispecific antibody cibisatamab as…
colorectal cancer
Checkmate 8HW is the first phase III study to assess first-line nivolumab plus ipilimumab in patients with unresectable microsatellite instability-high/mismatch…
Chemotherapy resistance is often driven by cancer cells entering into a slow-cycling or dormant state to evade therapy-induced cell death….
VHIO has participated in this project coordinated by INCLIVA, which has made it possible to expand knowledge about this type…
A study led by researchers at the Hospital del Mar Medical Research Institute shows that the oxaliplatin administered in some…
The annual ASCO Symposium on Gastrointestinal Cancers took place from 19-21 January. Josep Tabernero, Director of VHIO, presented the results…
The multicenter randomized phase III BREAKWATER trial, spearheaded by VHIO, is the first to evaluate the combination of study drugs…
